CTNM vs DXCM · $429.6M cap vs P/E 63, rev $2.50B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus DexCom Inc (DXCM) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
DexCom Inc (DXCM) is a medical devices company listed on US.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
CTNM currently screens at market cap $429.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Not investment advice. Open the CTNM and DXCM stock pages for the full models.
Not investment advice.